Acute hepatomegaly with severe liver toxicity due to all-trans-retinoic acid

Haematologica

Volumn 85, Issue 5, 2000, Pages 551-552

  Perea, Granada ^a   Salar, Antonio ^a   Altés, Alberto ^a   Brunet, Salut ^a   Sierra, Jorge ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Acute promyelocytic leukemia; Adverse effects; All trans retinoic acid; Hepatomegaly; Hepatotoxicity

Indexed keywords

RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; CASE REPORT; DRUG TOLERABILITY; HEPATOMEGALY; HUMAN; KIDNEY FAILURE; LIVER INJURY; LIVER TOXICITY; MALE;

ACUTE DISEASE; ADULT; BILIRUBIN; HEPATOMEGALY; HUMANS; KIDNEY FAILURE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; TRANSAMINASES; TRETINOIN;

EID: 0033946268     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Warrell RP Jr, de Thé H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993; 329:177-89.
2. De Botton S, Dombret H, Sanz M, et al. Incidence, clinical features, and outcome of all-trans retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1998; 92:2712-8.
3. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr. The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 1992; 117:292-6.
4. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76:1704-9.
5. Adamson PC, Reaman G, Finklestein JZ, et al. Phase I trial and pharmacokinetic study of all-trans retinoic acid administered on an intermittent schedule in combination with interferon-α2a in pediatric patients with refractory cancer. J Clin Oncol 1997; 15:3330-7.
6. Shibata K, Shimamoto Y, Ishibashi S, Tominaga H, Suga K, Yamaguchi M. Life-threatening hepatic toxicity caused by all-trans-retinoic acid in a patient with acute promyelocytic leukemia. Clin Lab Haematol 1994; 16:191-5.
7. Goss GD, McBurney MW. Physiological and clinical aspects of vitamin A and its metabolites. Crit Rev Cl Lab Sci 1992; 29:185-215.
8. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90:1014-21.
9. Estey EH, Thall PF, Pierce S, et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999; 93:2478-84.
10. Sacchi S, Kantarjian HM, O'Brien S, et al. Excessive toxicity with the combination of alpha interferon (IFN-α), low dose cytosine arabinoside (LD-ARA-C) and all-trans retinoic acid (ATRA) in patients with chronic myelogenous leukemia (CML). Blood 1998; 92 (suppl 1):4067.